Wire · opportunities
FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA approved zilganersen (Zanvastro) as the first disease-modifying treatment for Alexander disease, based on data showing improved gait speed and motor function in pediatric and adult patients. The approval includes patients from infancy through adulthood and requires intrathecal dosing every 12 weeks, with monitoring for aseptic meningitis and other side effects.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 3 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You must prepare to navigate complex intrathecal delivery and patient monitoring in ultra-rare neurology treatments as FDA opens this market with zilganersen. Early movers can establish clinical trust and patient access before competitor therapies emerge.
◆ Coverage
15 sources · first reported 3 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics